Advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression.
VIEW PRODUCT PIPELINEAbout
We are a neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing innovative therapeutics to improve the lives of people living with neurological and psychiatric disorders..
Read MoreLatest News
Xenon Reports First Quarter 2025 Financial Results and Provides Business Update
Xenon to Report Q1 2025 Financial Results on May 12, 2025
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xenon to Showcase Long-Term 36-Month Azetukalner Data at AAN 2025
View All News >
Investors
Visit our Investor page for News Releases, Annual & Quarterly Reports, Webcasts & Events
View Investor Area
